Please login to the form below

Not currently logged in
Email:
Password:

CMV

This page shows the latest CMV news and features for those working in and with pharma, biotech and healthcare.

Analysts look beyond Keytruda in Merck’s future

Analysts look beyond Keytruda in Merck’s future

He added that Gardasil’s potential “is really significant going forward, but behind that are opportunities in next generation pneumococcal, RSV, CMV, dengue and other areas.”.

Latest news

  • Moderna CEO makes case for firm’s lofty valuation Moderna CEO makes case for firm’s lofty valuation

    Vaccines for diseases such as flu are unlikely to turn into big sellers – although Bancel reckons its candidate for cytomegalovirus (CMV) is pitching at a “several billion dollar” market.

  • EC grants MSD’s Prevymis orphan product designation EC grants MSD’s Prevymis orphan product designation

    The European Commission has granted Merck Sharp &Dohme’s new CMV prevention medication orphan medicinal product status, handing it a package of benefits that will include some market exclusivity. ... The status for Prevymis’ (letermovir) covers the

  • Shire’s Maribavir wins US breakthrough therapy designation Shire’s Maribavir wins US breakthrough therapy designation

    The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to Shire’s investigational treatment for cytomegalovirus (CMV) infection in transplant patients. ... According to Shire, the investigational treatment operates by

  • CHMP backs MSD’s CMV infection treatment CHMP backs MSD’s CMV infection treatment

    week. Prevymis is one of a new class of non-nucleoside inhibitors and aims to prevent cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem ... In 2014, there were 1, 346 non-paediatric

  • Merck says drug for CMV in transplant patients hits targets Merck says drug for CMV in transplant patients hits targets

    CMV is a herpes virus, infecting 50-90% of the adult population, with a majority remaining without symptoms. ... The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of

More from news
Approximately 4 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    VPM. Cevec.  Licence. CMV dense body technology in vaccines. Biological E .

  • Pharma deals during October 2012 Pharma deals during October 2012

    CMV) and related assets. Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics